Grünenthal GmbH

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Private

Established: 1946-01-01

Employees: 1K

Market Cap: -

Website: http://www.grunenthal.com

Clinical Trials

A Clinical Study in Healthy Subjects Which Aims to Investigate the Safety, the Tolerability and the Effects of GRT0151Y and How the Compound is Taken up and Excreted From the Body

Phase 1

Completed

Conditions: Acute Pain

Interventions: Drug: 225 mg GRT0151Y
Drug: 150 mg GRT0151Y
Drug: 100 mg GRT0151Y
Drug: 125 mg GRT0151Y
Drug: Matching placebo

First Posted Date: 2018-12-03

Last Posted Date: 2018-12-03

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 48

Registration Number: NCT03761407

Locations: 🇫🇷
ASTER, Paris, France

Bioequivalence of Two Fixed-dose Combination Tablets Containing Estradiol and Nomegestrol Acetate

Phase 1

Withdrawn

Conditions: Bioequivalence

Interventions: Drug: Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Reference Product)
Drug: Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Test Product)

First Posted Date: 2018-11-21

Last Posted Date: 2019-07-15

Lead Sponsor: Grünenthal GmbH

Registration Number: NCT03749733

Locations: 🇲🇽
Investigacíon Farmacológica y Biofarmacéutica (IFaB), S.A.P.I. de C.V., Mexico City, Mexico

A Study With Lido-Patch and Placebo Plaster in Patients Suffering From Postherpetic Neuralgia (PHN)

Phase 3

Completed

Conditions: Post Herpetic Neuralgia

Interventions: Drug: Lidocaine 5% medicated Plaster
Drug: Placebo Plaster

First Posted Date: 2018-11-19

Last Posted Date: 2023-09-13

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 265

Registration Number: NCT03745404

Characterization of the Pharmacokinetics of a Vaginal Ring With 2.0 g Progesterone in Post-menopausal Women

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: Progesterone vaginal ring

First Posted Date: 2018-11-09

Last Posted Date: 2019-06-05

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 106

Registration Number: NCT03737656

Locations: 🇲🇽
Investigacíon Farmacológica y Biofarmacéutica (IFaB), S.A.P.I. de C.V., Mexico City, Mexico

Tramadol/Diclofenac Fixed-dose Combination Phase III Trial in Acute Pain After Third Molar Extraction

Phase 3

Completed

Conditions: Acute Pain

Interventions: Drug: Tramadol/Diclofenac 25/25
Drug: Tramadol 50
Drug: Tramadol/Diclofenac 50/50
Drug: Diclofenac 50

First Posted Date: 2018-10-22

Last Posted Date: 2019-07-24

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 1151

Registration Number: NCT03714672

Locations: 🇲🇽
University, San Luis Potosí, Mexico
🇲🇽
Private Clinic, Puebla, Mexico

A Clinical Study to Compare MAR-CUTIS With Dermabond Advanced

Not Applicable

Terminated

Conditions: Surgical Incision
Lacerations
Wounds and Injuries

Interventions: Device: MAR-CUTIS
Device: Dermabond Advanced

First Posted Date: 2018-09-28

Last Posted Date: 2020-08-20

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 107

Registration Number: NCT03688880

Locations: 🇩🇪
010 - Charité Berlin, Berlin, Germany
🇪🇸
022 - Hospital General Universitario Gregorio Maranon, Madrid, Spain
🇫🇷
004 - CHU Amiens-Picardie, Amiens, France

and more 16 locations

Efficacy and Safety of Intravenous Neridronic Acid in Complex Regional Pain Syndrome (CRPS)

Phase 3

Terminated

Conditions: Complex Regional Pain Syndrome (CRPS)

Interventions: Drug: Placebo
Drug: Neridronic acid 100 mg

First Posted Date: 2018-06-19

Last Posted Date: 2020-08-05

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 267

Registration Number: NCT03560986

Locations: 🇸🇰
SK402 - MUDr. Beata Dupejova, neurologicka ambulancia sro, Banska Bystrica, Slovakia
🇺🇸
US410 - Alliance Research Centers, Laguna Hills, California, United States
🇺🇸
Us414 - Alexander Ford Md, Los Angeles, California, United States

and more 68 locations

Efficacy and Safety of Intravenous Neridronic Acid in CRPS

Phase 3

Terminated

Conditions: Complex Regional Pain Syndrome (CRPS)

Interventions: Drug: Neridronic acid 100 mg
Drug: Placebo

First Posted Date: 2018-05-21

Last Posted Date: 2020-08-06

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 182

Registration Number: NCT03530345

Locations: 🇺🇸
US013 - Inland Pain Medicine, Colton, California, United States
🇺🇸
US052 - Providere' Research Inc., West Covina, California, United States
🇺🇸
US020 - SIMEDHealth, Ocala, Florida, United States

and more 68 locations

A Study in Healthy Male Volunteers to Investigate the Safety and Tolerability of a Single Dose of Neosaxitoxin Alone and in Combination With Bupivacaine (With and Without Epinephrine) for Brachial Plexus Blockade

Phase 1

Terminated

Conditions: Anesthesia, Local
Anesthesia
Analgesia

Interventions: Combination Product: Neosaxitoxin combined with bupivacaine low (T2)
Combination Product: Neosaxitoxin combined with bupivacaine low and epinephrine (T1)
Drug: Neosaxitoxin (T3)
Combination Product: Bupivacaine low combined with epinephrine (C1)
Combination Product: Neosaxitoxin combined with epinephrine (T4)
Drug: Bupivacaine low (C3)
Drug: Bupivacaine high (C4)
Combination Product: Bupivacaine high combined with epinephrine (C2)
Combination Product: Neosaxitoxin combined with bupivacaine low and epinephrine
Combination Product: Neosaxitoxin combined with bupivacaine low

First Posted Date: 2018-01-16

Last Posted Date: 2018-10-11

Lead Sponsor: Grünenthal GmbH

Target Recruit Count: 242

Registration Number: NCT03399435

Locations: 🇳🇱
NL001, Groningen, Netherlands

A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults

Phase 1

Withdrawn

Conditions: Opioid-Related Disorders
Pain, Acute
Pain, Postoperative

Interventions: Drug: Norco 5Mg-325Mg Tablet
Drug: GRT7014 - Abuse Deterrent Tablet

First Posted Date: 2017-05-02

Last Posted Date: 2017-07-21

Lead Sponsor: Grünenthal GmbH

Registration Number: NCT03137017

Locations: 🇺🇸
US001: PRA Health Sciences, Lenexa, Kansas, United States

Home Terms & Conditions Privacy Policy